Stock info Gilead Sciences | Filter Basic-Info
Stock: Gilead Sciences (US Tech), ISIN: US3755581036
| Last Price | 111.06 | Max Price | 111.06 |
| Min Price | 111.06 | 1 Year return | 0.00 |
| Sector | Health Care | Subsector | Biotechnology |
| Annual report 2020 |
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Gilead Sciences' mission is to advance the care of patients suffering from life-threatening diseases worldwide. In addition to Gilead Sciences' marketed products, Gilead Sciences has a clinical, preclinical and research pipeline focused on developing anti-infectives. Gilead Sciences’ stocks are traded in New York and the company is a component of the NASDAQ 100-index (ISIN: US3755581036/ Symbol: GILD).
Contact info:Street: Foster City, CA 94404Zip Code: CA 94404City: Foster CityCountry: USAPhone: (650) 5743000Email: investor_relations@gilead.comWebsite: www.gilead.comCEO: John C. MartinCFO: Robin L. Washington
Sector Review Gilead Sciences
| Year | Turnover | Total sector | Market share |
|---|---|---|---|
| 2019 | 20,025 | 135,969 | 14.73 % |
| 2020 | 20,215 | 152,939 | 13.22 % |
| 2021 | 24,019 | 227,396 | 10.56 % |
| 2022 | 25,491 | 260,129 | 9.80 % |
| 2023 | 24,570 | 214,794 | 11.44 % |
Advice Gilead Sciences
News Gilead Sciences
Gilead Sciences in top American dividend stocks
FDA puts partial clinical hold on Gilead's magrolimab + azacitidine studies
Gilead and Merck ink collaboration agreement for Keytruda/Trodelvy breast cancer study
Gilead and Novo Nordisk expand collaboration in NASH therapeutics
Gilead Sciences now in top highest dividend yields in America
Annual reports Gilead Sciences
| 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
Profile Gilead Sciences
Gilead Sciences
(US3755581036)/ GILDGilead Sciences has located her head office Foster City. Gilead Sciences mainly operates in the biotech sector. John C. Martin manages the company as a CEO. The CFO of Gilead Sciences the company is Robin L. Washington. The global biotech companies gained around 59 percent over the period 2006-2016. Since 2011 the sector is 70 percent higher and over the past year minus 59 percent.
The past year was a good year for Gilead Sciences investors
Over the last 12 months, that were loss-making period for the investors in Gilead Sciences, the stock lost around 28 percent. Over the period from December 2011 till December 2016 the stock rose on average 280 percent. Gilead Sciences's revenues between 2011 and 2015 were very volatile through the time and moved between 9,7 billion dollars and 32,64 billion dollars. Gilead Sciences's net incomes between 2011 and 2015 were very volatile and moved between 2,79 billion dollars and 18,11 billion dollars.
Gilead Sciences paid out dividends in the past 5 years. Over the past 5 years the stock delivered an average dividend return of 1,29 percent.
Gilead Sciences had about 7000 thousand employees at the end of 2015.
Gilead Sciences' balance mostly consists of equity
At the end of 2015 the American company had a balance sheet of around 51,84 billion dollars. The total debt of the biotech company was at the end of 2015 33,31 billion dollars, which equals around 64,25 percent of the total balance sheet. At the end of 2016 the American company was traded with a price/earnings-ratio of around 8. So investors paid 8 times the company's 2015's EPS. Based on the classical stock valuation theories the American stock can be seen as a value stock.
The biotech company's market capitalization (the number of shares outstanding times the market value) equaled around 139,71 billion dollars. At the end of 2015 around 1,42 billion stocks were listed.
On this page you can find all Gilead Sciences's financial reports. More information about Gilead Sciences can be found it's website. .
Results Gilead Sciences
| Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|---|
| Revenue |
30,054
|
28,906
|
21,763
|
19,292
|
20,025
|
20,215
|
| Costs |
13,380
|
16,064
|
17,906
|
14,536
|
15,221
|
20,115
|
| Profit |
16,674
|
12,842
|
3,857
|
4,756
|
4,804
|
100
|
| Margin of profit |
55.48
|
44.43
|
17.72
|
24.65
|
23.99
|
0.49
|
| ROI |
97.70
|
71.48
|
22.63
|
25.51
|
23.91
|
0.67
|
Balance Gilead Sciences
| Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|---|
| Equity |
17,066
|
17,965
|
17,040
|
18,647
|
20,093
|
14,903
|
| Debt |
30,554
|
36,231
|
41,548
|
36,872
|
34,881
|
41,108
|
| Total assets |
47,620
|
54,196
|
58,588
|
55,519
|
54,974
|
56,011
|
| Solvency |
35.84
|
33.15
|
29.08
|
33.59
|
36.55
|
26.61
|
| Cash |
13,451
|
11,314
|
21,265
|
26,235
|
21,723
|
6,065
|
| Cashflow |
19,567
|
16,215
|
9,918
|
7,324
|
8,157
|
6,687
|
| Employees |
0
|
0
|
0
|
0
|
0
|
|
| Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
| Cashflow / Debt |
0.64
|
0.45
|
0.24
|
0.20
|
0.23
|
0.16
|
Details Gilead Sciences
| Details |
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|
| Price |
101.19
|
71.61
|
71.64
|
62.55
|
64.98
|
| Eps |
9.00
|
2.00
|
3.00
|
3.00
|
|
| Price/earnings-ratio |
11.24
|
35.80
|
23.88
|
20.85
|
|
| Dividend |
1.00
|
1.00
|
1.00
|
2.00
|
2.00
|
| Dividend % |
0.99 %
|
1.40 %
|
1.40 %
|
3.20 %
|
1.80 %
|
| Payout % |
0.11
|
0.50
|
0.33
|
0.67
|
|
| Book value |
13.75
|
13.03
|
14.55
|
15.87
|
11.88
|
| Market to book |
0.14
|
0.18
|
0.20
|
0.25
|
0.11
|
| Cashflow per stock |
12.41
|
7.58
|
5.71
|
6.44
|
5.33
|
| Stocks |
1,307
|
1,308
|
1,282
|
1,266
|
1,254
|
| Market Cap |
132.255.33
|
93.665.88
|
91.842.48
|
79.188.30
|
139.269.24
|
Dividend Gilead Sciences
Price info Gilead Sciences
|
Date
|
Price
|
|---|---|
|
09 Jul 2025
|
111.06
|
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
|
